MedTrace Logo

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

NCT02633514 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2026-04-27

No results posted yet for this study

Summary

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Conditions

  • Thymoma and Thymic Carcinoma

Interventions

DRUG

Cisplatin

25mg/m2,iv gtt,d1-3

DRUG

Etoposide

75mg/m2,iv gtt,d1-3

RADIATION

radiotherapy

60Gy/30Fx

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Kailiang Wu, MD. PhD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633514 on ClinicalTrials.gov